The Sf-RVN® Platform
For Improving the Safety Profile of Your Baculovirus-Insect Cell Based Vaccines and Gene Therapies
Our Sf-RVN® Insect Cell Line offers a rhabdovirus-free alternative and enhances risk mitigation. Together with our chemically defined medium, EX-CELL® CD Insect Cell Medium, forms the Sf-RVN® Platform, providing a high performance platform optimal to produce recombinant proteins, viral vaccines such as viral like particles (VLP) and adeno-associated vectors (AAV) for gene therapy applications.
The baculovirus-insect cell system is widely used for production of virus-like particles (VLP), recombinant proteins and adeno-associated viruses (AAV) due to its flexibility, speed, simplicity and productivity. The majority of Spodoptera frugiperda cells (such as Sf9) contain a Rhabdovirus that is considered a process contaminant and must be eliminated (Hailun Ma et al. 2014). With the Sf-RVN® Platform, we provide an Sf-Rhabdovirus-free cell line that improves the safety profile of your bioprocesses paired with the EX-CELL® CD Insect Cell Medium, a chemically defined medium, specifically formulated to get excellent growth and productivity while adhering to evolving regulatory requirements. Combined, these two products form the Sf-RVN® Platform and offer an Sf-Rhabdovirus-free alternative for the BICS production of VLP vaccines, recombinant proteins and AAV based gene therapies.
To continue reading please sign in or create an account.Don't Have An Account?